UltraCharge clinches key partnership with Sinochem
Published 16-JAN-2018 12:10 P.M.
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
UltraCharge Limited (ASX:UTR) has entered into a Memorandum of Understanding (MOU) with China’s leading fluorine chemical manufacturer, Sinochem Lantian Co. Ltd. Sinochem Lantian is a subsidiary of Sinochem Group, which is a Chinese state-owned Fortune Global 500 company.
Having recently acquired a high performing, low cost electrolyte solution from Coorstek Speciality Chemicals, UTR’s electrolyte IP will facilitate the production of a superior electrolyte salt (LiFSI salt), which can increase battery lifespan and performance.
Because Sinochem Lantian is one of just several companies that produce LiFSI salt, the MOU is a crucial step forward for the company — which aims to produce a commercial lithium-ion battery solution.
Furthermore, the MOU provides an invaluable opportunity for UTR to capitalise on the burgeoning Chinese electric vehicle market. Due to its government’s policy on clean driving and greenhouse emissions, China has become the world’s leading electric vehicle consumer.
UTR believes its lithium-ion battery solutions are well suited to satisfy the increasing demand and market requirements of Chinese electric vehicle manufacturers.
“We are very pleased to be in partnership with Sinochem Lantian to develop our electrolyte IP,” UTR CEO, Kobi Ben-Shabat said.
“We are now in a position to offer battery manufacturers a full or tailored solution to enhance performance of lithium ion batteries. For the end user or consumer, this means a longer lifespan, higher voltage, low cost battery solution which is safe,” he said.
It should be noted here that UTR remains a speculative company and investors should seek professional financial advice if considering this stock for their portfolio.
An Israel-based company, UTR is focused on developing electric battery technologies. Its growing IP of battery tech includes:
- Anode for lithium-ion batteries: UTR has the exclusive rights to patented anode technology from Nanyang Technology in Singapore. This tech could provide a safer and faster charging battery by replacing the graphite in battery anodes with nanotube fibres made from titanium oxide.
- Cathode for lithium-ion batteries: The company has agreed to acquire the IP from ETV Energy in Israel. This IP could enable UTR to produce cathodes at half the cost of current commercial offerings.
- Electrolyte in lithium-ion batteries: UTR has now acquired a low cost, high performing electrolyte solution from US based company, Coorstek Speciality Chemicals. This IP is based around producing a superior electrolyte salt (LiFSI), which could significantly increase battery lifespan and performance.
- Ion flow battery: UTR has an exclusive licence agreement with Israeli company Epsilor. The agreement will provide access to Epsilor’s new ion flow battery tech, which is the only commercially viable energy storage of its type to date. It also boasts lower installation and operation costs than current market alternatives.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.